Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials
نویسندگان
چکیده
Marc Miravitlles*,1, Kai-Michael Beeh2 & Pablo Altman3 Department of Pneumology, Hospital Universitari Vall d’Hebron, Ciber de Enfermedades Respiratorias (Ciberes), P. Vall d’Hebron 119–129, 08035, Barcelona, Spain Insaf Institut für Atemwegsforschung GmbH, Biebricher Allee 34, D-65187 Wiesbaden, Germany Novartis Pharmaceuticals Corporation, 1 Health Plz, East Hanover, NJ 07936, USA *Author for correspondence: Fax: +34 93 2746 083 [email protected]
منابع مشابه
Statins and Pulmonary Hypertension in Chronic Obstructive Lung Disease
Chronic obstructive lung disease (COPD) is a chronic multisystem disease with a considerable burden. One of its most common complications is pulmonary artery hypertension (PAH). It has been demonstrated that the development of PAH is correlated with decreased quality of life and survival. Different medications have been proposed for the treatment of PAH, among which one can name statins. Howeve...
متن کاملOnce-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit
BACKGROUND Long-acting bronchodilators are central in the pharmacological management of patients with chronic obstructive pulmonary disease (COPD). The aim of this systematic review is to provide an overview of the studies evaluating the safety and clinical efficacy of inhaled glycopyrronium bromide, a novel long-acting muscarinic antagonist, in patients with COPD. METHODS This study was perf...
متن کاملProfile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment of COPD. Glycopyrronium is a novel LAMA, currently in development for COPD. Phas...
متن کاملClinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
BACKGROUND AND AIM Long-acting bronchodilators are the preferred option for maintenance therapy of patients with chronic obstructive pulmonary disease (COPD). The aim of this review is to provide an overview of the clinical studies evaluating the clinical efficacy of the once-daily fixed-dose dual bronchodilator combination of indacaterol and glycopyrronium bromide in patients suffering from CO...
متن کاملProfile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. The cornerstone of pharmacological treatment for COPD is bronchodilation. Inhaled glycopyrronium bromide is a long-acting muscarinic antagonist developed as a maintenance treatment for patients with COPD. Phase III trials have shown that glycopyrronium produces rapid and sustained bronchodilation with an e...
متن کامل